DOCSLIB.ORG

Cambridge University Press 978-1-107-03891-2 - Clinical Infectious Disease Edited by David Schlossberg Index More Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cambridge University Press 978-1-107-03891-2 - Clinical Infectious Disease Edited by David Schlossberg Index More Information Cambridge University Press 978-1-107-03891-2 - Clinical Infectious Disease Edited by David Schlossberg Index More information Index Page references in bold indicate tables; those in italic indicate figures. abacavir (ABC), 650 otitis media, 49 PCP pneumonia, 1151–1152, abdominal infections. See intra- pregnant patients, 618 See also Pneumocystis jirovecii abdominal infections viral hemorrhagic fevers, 1246 pneumonia (PCP) Abiotrophia spp., 1042 Achromobacter spp., 1046 pregnant patients, 616 A. defectiva, 247 A. denitrificans, 1046 progressive multifocal abscess A. xylosoxidans, 1046 leukoencephalopathy abdominal, 367–369 clinical syndromes, 1046 association, 529–531 diagnosis, 367 epidemiology, 1046 treatment, 533–534 treatment, 367–369, 380 Acinetobacter baumannii, 1045–1046 splenic abscess, 372 brain. See brain abscess multidrug resistance, 1046 toxoplasmic encephalitis, 1279–1280 breast, 620 nosocomial infections, 1045 Acrobacter, 810 coccidioidomycosis, 1144 pneumonia, 222 acrodermatitis chronica atropicans, cranial epidural, 500–501, 501 Acinetobacter spp., 1044–1046, See also 1062 dental, 64,66 Acinetobacter baumannii Actinomyces spp. (actinomycosis), 829 HACEK organism-associated, 904, catheter-related infections, 721, 723 clinical presentation, 829–830 906 epidemiology, 1045 abdominal disease, 830–831 iliopsoas. See iliopsoas abscess (IPA) meningitis, 477 CNS disease, 831 intraperitoneal, 366, 375, 380 post-transplant infection, 576 disseminated disease, 831 lacrimal sac, 116 sepsis, 15 musculoskeletal disease, 831 liver. See liver abscess urinary tract infection, 723 oral–cervicofacial disease, 830, macular, 113, 114 acquired immunodeficiency 830 orbital, 118–119, 119 syndrome (AIDS). See also human pelvic disease, 831 subperiosteal, 119 immunodeficiency virus (HIV) thoracic disease, 830 pancreatic, 366, 601 brain abscess, 498–499 diagnosis, 831 pelvic, 418, 420 CNS lesions, 497 osteomyelitis, 452, 831 pericolic, 362 cryptococcal infection pathogenesis, 829 perinephric, 434, 435, 436, 437–438 meningitis, 1130–1132, 1131 sialadenitis, 72 diabetic patients, 588 therapy, 1130–1132 treatment, 831–834 peritonsillar, 35 cytomegalovirus infection antimicrobial therapy, 831–832, renal, 434–437, 435, 436 retinitis, 102, 1164–1165 832 retroperitoneal, 367 therapy, 1164–1165 co-isolates, 832–833 retropharyngeal, 35 esophageal infections, 324–325 home therapy, 832 salivary gland, 69 gastroenteritis, 337 immunocompromised hosts, 833 spinal. See spinal epidural abscess evaluation, 339 refractory disease, 833 splenic, 371, See splenic abscess management, 340 surgery or percutaneous thyroid, 43, 45–46, 46 human herpesvirus 6 infection, drainage, 833 tubo-ovarian, 418 1201 Actinomyces spp. (actinomycosis) Acanthamoeba spp., 93, 805 Kaposi’s sarcoma, 1203 A. israelii, 117 keratitis, 88, 93–94, 94 lympadenopathy, 189 Actinomyces-like organisms (ALO), 833 treatment, 94 mucormycosis, 1120, 1122 acute disseminated encephalomyelitis waterborne infections, 804, 805–806 Mycobacterium avium complex, (ADEM), 134, 518 acetaminophen 1020 diagnosis, 518 chickenpox, 1229 therapy, 1025 acute glomerulonephritis (AGN), Epstein–Barr virus infection, 1187 parvovirus B19 infection, 1218 1000, 1002 1415 © in this web service Cambridge University Press www.cambridge.org Cambridge University Press 978-1-107-03891-2 - Clinical Infectious Disease Edited by David Schlossberg Index More information acute mountain sickness (AMS), 783 adefovir, 1355 pancreatitis, 601 acute otitis externa (AOE). See otitis adverse effects, 1355 peritonitis, 599–600 externa drug interactions, 1355 pneumonia, 597–599 acute otitis media (AOM). See otitis hepatitis B infection, 1355 anaerobic, 598 media pharmacokinetics, 1355 gram-negative, 598–599 acute respiratory distress syndrome adenoviruses pneumococcal, 54–55 (ARDS), 221 conjunctivitis, 81 tuberculosis, 599 acute retinal necrosis (ARN), 99, 105, diagnosis, 82 alkylating agents, 564 105–106 gastroenteritis, 337 allergic bronchopulmonary HIV-infected patients, 685 myocarditis, 260–263 aspergillosis (ABPA), 1117 treatment, 105 adult inclusion conjunctivitis, 86 allergic fungal sinusitis, 62 acute retroviral syndrome (ARS), 1186 adult-onset Still’s disease (AOSD), allergic reactions. See hypersensitivity acute rheumatic fever (ARF), 1000, 455, 457 reactions 1000–1002 adverse drug reactions (ADRs), 1371, altitude sickness, 783 diagnostic criteria, 1000 See also hypersensitivity reactions; amantadine, 1355 primary prevention, 1001 specific drugs influenza, 1208 secondary prevention, 1001–1002 aerobic exercise, chronic fatigue chemoprophylaxis, 1209 therapy, 1001 syndrome management, 29 amebiasis. See Entamoeba histolytica acute suppurative thyroiditis (AST), 42 Aerococcus spp., 1042–1043 amebic liver abscess, 787, 1318, clinical manifestations, 44–45 A. urinae, 1042 1318–1321 diagnosis, 45–46 A. viridans, 1042 clinical presentation, 1318–1319 fine-needle aspiration, 46 Aeromonas hydrophila, 791, 805 diagnosis, 1319–1320 imaging, 45–46 aerosolized red tide respiratory treatment, 1320, 1320–1321 management, 46 irritation (ARTRI), 809 aspiration, 1321 microbiology, 43–44, 44 African eyeworm, 1261 amikacin, 1336 pathogenesis, 42–43 Aggregatibacter spp., 904, See also Mycobacterium abscessus, 1026 acyclovir, 1353–1355 HACEK organisms Mycobacterium avium complex, adverse effects, 1354–1355 albendazole 1024–1025 chronic fatigue syndrome, 29 anisakiasis, 1257 Mycobacterium kansasii, 1025 cytomegalovirus ascariasis, 1252 Mycobacterium tuberculosis prophylaxis, 1165 Baylisascaris procyonis, 1266 (tuberculosis), 1018 drug interactions, 1355 cutaneous larva migrans, 1266 nocardiosis, 952 encephalitis, 492–493, 683, 1198, 1354 cysticercosis, 1276 Pseudomonas aeruginosa, 967 Epstein–Barr virus, 1188, 1354 echinococcosis, 1277–1278 amino acid abbreviations, 667 esophageal infections, 329, 331 filariasis, 1261 aminoglycosides, 1336, See also specific prophylaxis, 329 giardiasis, 808, 1314 drugs herpes simplex virus, 617, 1198 gnathostomiasis, 1266 brucellosis, 867 genital herpes, 410, 1197, 1354 hookworms, 1253 children, 868 hepatitis, 293 loiasis, 1262 cholangitis, 311 herpes labialis, 1196 Microsporida, 1317 dialysis-related infection, 624, neonates, 613, 1198 toxocariasis, 518, 1265 627 meningitis, 485 trichinellosis, 1259 elderly patients, 603 myelitis, 515 trichuriasis, 1252 endocarditis, 897 nosocomial pneumonia, 224 Alcaligenes faecalis, 1047 enterococcal infections, 897 pharmacokinetics, 1354 Alcaligenes spp., 1046–1047 iliopsoas abscess, 467 post-transplant infection, 581 A. faecalis, 1046 neonates, 609 pregnant patients, 617, 620 clinical syndromes, 1047 perinephric abscess, 438 retinitis, 105 epidemiology, 1047 peritonitis, 376 varicella-zoster virus, 493, 620, 683, alcoholic patients, 597, 598 Pseudomonas aeruginosa, 967 1354 bacteremia and sepsis, 600–601 resistance, 1336 chickenpox, 1229 diphtheria, 601 sepsis, 18 herpes zoster (shingles), 677, endocarditis, 601 splenic abscess, 374 1231 hepatitis, 601–602 urinary tract infection, 426 adalimumab, 569 HIV, 602 catheter-related, 725 infection risk, 569–570 immunologic defects, 597 amnesic shellfish poisoning, 344 1416 Index © in this web service Cambridge University Press www.cambridge.org Cambridge University Press 978-1-107-03891-2 - Clinical Infectious Disease Edited by David Schlossberg Index More information amoxicillin, 1334 immunocompromised patients, anaerobic infections, 835, 835, See also actinomycosis, 832 1132 specific infections anthrax, postexposure meningitis, 672, 683, 1129–1130 antibiotic resistance, 838, 842 prophylaxis, 846 dialysis-related infection, 627 beta-lactamase-producing dental infection, 66 echinococcosis, 1278 anaerobes, 838 Helicobacter pylori, 912 endophthalmitis, 112, 1110 collection and transport of Lyme disease, 1062 esophageal infections, 327–328 specimens, 836–837 Lyme arthritis, 1064 histoplasmosis, 686, 1136 diabetic foot ulcers, 838 otitis media, 50–53, 55, 964 keratitis, 95 features of, 836 Pasteurella multocida, 955 leishmaniasis, 1302, 1310–1311 female genital tract infections, 837 pharyngotonsillitis, 37 lipid formulations, 1347 intra-abdominal infections, 837 pneumonia, 963 mucormycosis, 586, 1121–1122 pleuropulmonary infections, 837 pregnant patients, 615 neonates, 611 skin and soft-tissue infections, 838 Salmonella infections, 982 neutropenic patients, 554, 557 sources of, 835, 835 chronic carriage, 983 sepsis, 20 treatment, 837–842 urethritis, 390 splenic abscess, 374 antibiotic susceptibility, 839, 840 urinary tract infection, 425, 615 sporotrichosis, 1126 types of infection, 835–836, 836 amoxicillin–clavulanate, 1334 thrombophlebitis, 274 analgesics. See also specific drugs acute otitis media, 52 urinary tract infection, 431 otitis media, 49 Haemophilus influenzae, 922 cystitis, 432 Anaplasma phagocytophilum, 1062, Moraxella catarrhalis, 864 diabetic patients, 588 1098–1099, 1100 neutropenic patients, 556 pyelonephritis, 432 anaplasmosis, 794, 1098–1101, 1099, nocardiosis, 953 renal candidiasis, 432 1100 otitis media, 52, 964 vulvovaginal candidiasis, babesiosis coinfection, 1299–1300 Pasteurella multocida, 956 398 diagnosis, 1099–1101 pneumonia, 963 zygomycete infections, 554 therapy, 1101 alcoholic patients, 598 ampicillin, 1334 Ancylostoma braziliense, 1252, 1265 pregnant patients, 615 cholangitis, 311 Ancylostoma caninum, 1252, 1265 pressure ulcers, 605 dialysis-related infection, 627 Ancylostoma ceylanicum, 1252 prostatitis, 416 endocarditis, 249, 897–898 Ancylostoma duodenale, 1250, 1252 sinusitis, 60 HACEK organism-associated, Angiostrongylus
Load more

Recommended publications
  • WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/134709 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/05 (2006.01) A61P 31/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/CA20 14/000 174 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 4 March 2014 (04.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13/790,91 1 8 March 2013 (08.03.2013) US (84) Designated States (unless otherwise indicated, for every (71) Applicant: LABORATOIRE M2 [CA/CA]; 4005-A, rue kind of regional protection available): ARIPO (BW, GH, de la Garlock, Sherbrooke, Quebec J1L 1W9 (CA). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (72) Inventors: LEMIRE, Gaetan; 6505, rue de la fougere, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Sherbrooke, Quebec JIN 3W3 (CA).
    [Show full text]
  • HACEK Endocarditis: State-Of-The-Art Matthieu Revest, Gérald Egmann, Vincent Cattoir, Pierre Tattevin
    HACEK endocarditis: state-of-the-art Matthieu Revest, Gérald Egmann, Vincent Cattoir, Pierre Tattevin To cite this version: Matthieu Revest, Gérald Egmann, Vincent Cattoir, Pierre Tattevin. HACEK endocarditis: state- of-the-art. Expert Review of Anti-infective Therapy, Expert Reviews, 2016, 14 (5), pp.523-530. 10.1586/14787210.2016.1164032. hal-01296779 HAL Id: hal-01296779 https://hal-univ-rennes1.archives-ouvertes.fr/hal-01296779 Submitted on 10 Jun 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. HACEK endocarditis: state-of-the-art Matthieu Revest1, Gérald Egmann2, Vincent Cattoir3, and Pierre Tattevin†1 ¹Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes; ²Department of Emergency Medicine, SAMU 97.3, Centre Hospitalier Andrée Rosemon, Cayenne; 3Bacteriology, Pontchaillou University Hospital, Rennes, France †Author for correspondence: Prof. Pierre Tattevin, Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, 2, rue Henri Le Guilloux, 35033 Rennes Cedex 9, France Tel.: +33 299289564 Fax.: + 33 299282452 [email protected] Abstract The HACEK group of bacteria – Haemophilus parainfluenzae, Aggregatibacter spp. (A. actinomycetemcomitans, A. aphrophilus, A. paraphrophilus, and A. segnis), Cardiobacterium spp. (C. hominis, C. valvarum), Eikenella corrodens, and Kingella spp.
    [Show full text]
  • Pseudomonas Skin Infection Clinical Features, Epidemiology, and Management
    Am J Clin Dermatol 2011; 12 (3): 157-169 THERAPY IN PRACTICE 1175-0561/11/0003-0157/$49.95/0 ª 2011 Adis Data Information BV. All rights reserved. Pseudomonas Skin Infection Clinical Features, Epidemiology, and Management Douglas C. Wu,1 Wilson W. Chan,2 Andrei I. Metelitsa,1 Loretta Fiorillo1 and Andrew N. Lin1 1 Division of Dermatology, University of Alberta, Edmonton, Alberta, Canada 2 Department of Laboratory Medicine, Medical Microbiology, University of Alberta, Edmonton, Alberta, Canada Contents Abstract........................................................................................................... 158 1. Introduction . 158 1.1 Microbiology . 158 1.2 Pathogenesis . 158 1.3 Epidemiology: The Rise of Pseudomonas aeruginosa ............................................................. 158 2. Cutaneous Manifestations of P. aeruginosa Infection. 159 2.1 Primary P. aeruginosa Infections of the Skin . 159 2.1.1 Green Nail Syndrome. 159 2.1.2 Interdigital Infections . 159 2.1.3 Folliculitis . 159 2.1.4 Infections of the Ear . 160 2.2 P. aeruginosa Bacteremia . 160 2.2.1 Subcutaneous Nodules as a Sign of P. aeruginosa Bacteremia . 161 2.2.2 Ecthyma Gangrenosum . 161 2.2.3 Severe Skin and Soft Tissue Infection (SSTI): Gangrenous Cellulitis and Necrotizing Fasciitis. 161 2.2.4 Burn Wounds . 162 2.2.5 AIDS................................................................................................. 162 2.3 Other Cutaneous Manifestations . 162 3. Antimicrobial Therapy: General Principles . 163 3.1 The Development of Antibacterial Resistance . 163 3.2 Anti-Pseudomonal Agents . 163 3.3 Monotherapy versus Combination Therapy . 164 4. Antimicrobial Therapy: Specific Syndromes . 164 4.1 Primary P. aeruginosa Infections of the Skin . 164 4.1.1 Green Nail Syndrome. 164 4.1.2 Interdigital Infections . 165 4.1.3 Folliculitis .
    [Show full text]
  • A. Fastidious Organisms MCQ 1 Explanation: the Most Common
    MCQ Answer 1: A. Fastidious organisms MCQ 1 Explanation: The most common cause of culture-negative infective endocarditis in patients who have not been treated previously with antibiotics is fastidious organisms (1). In our patient, serology for Bartonella, Pasteurella and Coxiella was negative, but the Brucella antibody titer was 1:160 (reference range <1:20). Brucella titers higher than 1:160 in conjunction with a compatible clinical presentation are considered highly suggestive of infection especially in a non-endemic area (2), (3). Brucellosis can affect any organ system and cardiac involvement is rare, but endocarditis is the main cause of death due to brucellosis. Ideally, the diagnosis should be made by culture, however this test has a low sensitivity, is time-consuming, and poses a health risk for laboratory staff (4). HACEK organisms used to be considered the most common agent of culture-negative endocarditis, but with the current blood culture techniques, they can be easily isolated when incubated for at least five days. In our patient, the HACEK organism culture was negative at 5 days (5). Antibacterial therapy prior to blood culture sampling is a common cause of culture negative endocarditis. Our patient received empiric antibiotic therapy after the blood cultures were drawn. Valvular vegetations can be caused by noninfectious conditions and should be considered in the differential diagnoses of any patient with endocarditis. Nonbacterial thrombotic endocarditis (NBTE), such as marantic or Libman-Sachs endocarditis, happens in the setting of systemic lupus erythematosus, malignancy, or hypercoagulable state. The vegetations of NBTE are composed of fibrin thrombi that usually deposit on normal or minimally degenerated valves.
    [Show full text]
  • Blood Culture Bottles Incubation Period, 5 Days Or More?
    February 2015 02/2015 NEWSLETTER Best Practices in Blood Culture Collection Blood culture bottles incubation period, 5 days or more? Introduction Blood is one of the most important specimens re- ceived by the microbiology laboratory for culture, and culture of blood is the most sensitive method for de- tection of bacteremia or fungemia. As we all know that the blood stream infection is one of the most se- rious problems in all infectious diseases. In general, adult patients with bacteremia are likely to have low quantities of bacteria in the blood, even in the setting of severe clinical symptoms. In addition, bacteremia in adults is generally intermittent. For this reason, multiple blood cultures, each containing large volumes of blood, are required to detect bacteraemia. Prior to initiation of antimicrobial therapy, at least two sets of blood cultures taken from separate venipuncture sites should be obtained. The technique, number of cultures, and volume of blood are more important factors for detection of bacteremia than timing of culture collection. Length of Incubation of Blood Cultures In routine circumstances, using automated continuous monitoring systems such as Becton Dickinson BACTEC System, blood cultures need not be incubated for longer than 5 days (1, 2, 3, 4, 5). For laborato- ries using manual blood culture systems, 7 days should suffice in most circumstances (6). Patient suspected Infectious Endocarditis (IE) A recent study at the Mayo Clinic, in which one of the widely used continuous monitoring blood culture systems was used, demonstrated that 99.5% of non-endocarditis BSIs and 100% of endocarditis epi- sodes were detected within 5 days of incubation (1).
    [Show full text]
  • Microbiology Course Specification 1St, 2Nd Year of M.B.B.Ch
    Faculty of Medicine Aswan University Microbiology Course Specification 1st, 2nd year of M.B.B.Ch. Program (Integrated system) 2019-2020 No. ILOs Practical Topic wks. hrs 1. B.1, C.1 Lab safety -Microscope 1st 2hrs D.1, D2 2. A6, B3 Sterilization, disinfection and 1st 2hrs D1, D2 antisepsis 3. A2, B.1 Laboratory diagnosis of bacterial 2nd 2 hrs C1, C2 infection (Simple and Gram’s stain) D1, D2 4. A6, B3 Ziehl Neelsen stain 2nd 2hrs 5. A3, B.1, Laboratory diagnosis of bacterial 3rd 2hrs C3 infection (Culture media I) D1, D2 6. A3, B1, Laboratory diagnosis of bacterial 3rd 2hrs C3, infection (Culture media II) D1, D2 7. A3, B2, , Laboratory diagnosis of bacterial 4th 2hrs C3, D1, infection (Biochemical reactions D2 Molecular diagnostic techniques) 8. A7, B.4 Antimicrobial susceptibility testing 4th 2hrs 9. A8, B5, Laboratory diagnosis of viral 5th 2hrs C5, D1, infections D2 A8, C2, Laboratory diagnosis of fungal 01. B.6, D1, 5th infections D2 A10, 10. B.7, C4, Serology I 6th D1, D2 A10, 12. B.7, C4 Serology II 6th D.1, D2 A10, 13. B.7, C4 Serology III 7th D.1, D2 A20, 04. B12, C8- Basics of infection control 7th 9 A2- Memorize the microorganism morphology A3- Recall bacterial growth requirements and replication. A6- Describe different methods of sterilization A7- Recognize proper selection of antimicrobials. A8- Recall general knowledge in the field of viral and fungal diseases. A10- Identify the role of the immune system against microbial infection. A20- State the basics of infection control B1- Differentiate the microorganism morphology B2- Explain genotypic variations and recombinant DNA technology B3- Compare between the different sterilization methods.
    [Show full text]
  • | Oa Tai Ei Rama Telut Literatur
    |OA TAI EI US009750245B2RAMA TELUT LITERATUR (12 ) United States Patent ( 10 ) Patent No. : US 9 ,750 ,245 B2 Lemire et al. ( 45 ) Date of Patent : Sep . 5 , 2017 ( 54 ) TOPICAL USE OF AN ANTIMICROBIAL 2003 /0225003 A1 * 12 / 2003 Ninkov . .. .. 514 / 23 FORMULATION 2009 /0258098 A 10 /2009 Rolling et al. 2009 /0269394 Al 10 /2009 Baker, Jr . et al . 2010 / 0034907 A1 * 2 / 2010 Daigle et al. 424 / 736 (71 ) Applicant : Laboratoire M2, Sherbrooke (CA ) 2010 /0137451 A1 * 6 / 2010 DeMarco et al. .. .. .. 514 / 705 2010 /0272818 Al 10 /2010 Franklin et al . (72 ) Inventors : Gaetan Lemire , Sherbrooke (CA ) ; 2011 / 0206790 AL 8 / 2011 Weiss Ulysse Desranleau Dandurand , 2011 /0223114 AL 9 / 2011 Chakrabortty et al . Sherbrooke (CA ) ; Sylvain Quessy , 2013 /0034618 A1 * 2 / 2013 Swenholt . .. .. 424 /665 Ste - Anne -de - Sorel (CA ) ; Ann Letellier , Massueville (CA ) FOREIGN PATENT DOCUMENTS ( 73 ) Assignee : LABORATOIRE M2, Sherbrooke, AU 2009235913 10 /2009 CA 2567333 12 / 2005 Quebec (CA ) EP 1178736 * 2 / 2004 A23K 1 / 16 WO WO0069277 11 /2000 ( * ) Notice : Subject to any disclaimer, the term of this WO WO 2009132343 10 / 2009 patent is extended or adjusted under 35 WO WO 2010010320 1 / 2010 U . S . C . 154 ( b ) by 37 days . (21 ) Appl. No. : 13 /790 ,911 OTHER PUBLICATIONS Definition of “ Subject ,” Oxford Dictionary - American English , (22 ) Filed : Mar. 8 , 2013 Accessed Dec . 6 , 2013 , pp . 1 - 2 . * Inouye et al , “ Combined Effect of Heat , Essential Oils and Salt on (65 ) Prior Publication Data the Fungicidal Activity against Trichophyton mentagrophytes in US 2014 /0256826 A1 Sep . 11, 2014 Foot Bath ,” Jpn .
    [Show full text]
  • Read Ebook {PDF EPUB} Pseudo by Dysonrules
    Read Ebook {PDF EPUB} Pseudo by dysonrules Pseudoreplication: choose your data wisely¶ Many studies strive to collect more data through replication: by repeating their measurements with additional patients or samples, they can be more certain of their numbers and discover subtle relationships that aren’t obvious at first glance. We’ve seen the value of additional data for improving statistical power and detecting small differences. But what exactly counts as a replication? Let’s return to a medical example. I have two groups of 100 patients taking different medications, and I seek to establish which medication lowers blood pressure more. I have each group take the medication for a month to allow it to take effect, and then I follow each group for ten days, each day testing their blood pressure. I now have ten data points per patient and 1,000 data points per group. Brilliant! 1,000 data points is quite a lot, and I can fairly easily establish whether one group has lower blood pressure than the other. When I do calculations for statistical significance I find significant results very easily. But wait: we expect that taking a patient’s blood pressure ten times will yield ten very similar results. If one patient is genetically predisposed to low blood pressure, I have counted his genetics ten times. Had I collected data from 1,000 independent patients instead of repeatedly testing 100, I would be more confident that differences between groups came from the medicines and not from genetics and luck. I claimed a large sample size, giving me statistically significant results and high statistical power, but my claim is unjustified.
    [Show full text]
  • Dermatology in the ER
    DRUG ERUPTIONS and OTHER DISORDERS Lloyd J. Cleaver D.O. , F.A.O.C.D, F.A.A.D. Professor of Dermatology ATSU-Kirksville College of Osteopathic Medicine INTERNAL MEDICINE BOARD REVIEW COURSE I Disclosures No Relevant Financial Relationships DRUG ERUPTIONS Drug Reactions 3 things you need to know 1. Type of drug reaction 2. Statistics What drugs are most likely to cause that type of reaction? 3. Timing How long after the drug was started did the reaction begin? Clinical Pearls Drug eruptions are extremely common Tend to be generalized/symmetric Maculopapular/morbilliform are most common Best Intervention: Stop the Drug! Do not dose reduce Completely remove the exposure How to spot the culprit? Drug started within days to a week prior to rash Can be difficult and take time Tip: can generally exclude all drugs started after onset of rash Drug eruptions can continue for 1-2 weeks after stopping culprit drug LITT’s drug eruption database Drug Eruptions Skin is one of the most common targets for drug reactions Antibiotics and anticonvulsants are most common 1-5% of patients 2% of all drug eruptions are “serious” TEN, DRESS More common in adult females and boys < 3 y/o Not all drugs cause eruptions at same rate: Aminopenicillins: 1.2-8% of exposures TMP-SMX: 2.8-3.7% NSAIDs: 1 in 200 Lamotrigine: 10% Drug Eruptions Three basic rules 1. Stop any unnecessary medications 2. Ask about non-prescription medications Eye drops, suppositories, implants, injections, patches, vitamin and health supplements, friend’s medications
    [Show full text]
  • Bacteriology
    SECTION 1 High Yield Microbiology 1 Bacteriology MORGAN A. PENCE Definitions Obligate/strict anaerobe: an organism that grows only in the absence of oxygen (e.g., Bacteroides fragilis). Spirochete Aerobe: an organism that lives and grows in the presence : spiral-shaped bacterium; neither gram-positive of oxygen. nor gram-negative. Aerotolerant anaerobe: an organism that shows signifi- cantly better growth in the absence of oxygen but may Gram Stain show limited growth in the presence of oxygen (e.g., • Principal stain used in bacteriology. Clostridium tertium, many Actinomyces spp.). • Distinguishes gram-positive bacteria from gram-negative Anaerobe : an organism that can live in the absence of oxy- bacteria. gen. Bacillus/bacilli: rod-shaped bacteria (e.g., gram-negative Method bacilli); not to be confused with the genus Bacillus. • A portion of a specimen or bacterial growth is applied to Coccus/cocci: spherical/round bacteria. a slide and dried. Coryneform: “club-shaped” or resembling Chinese letters; • Specimen is fixed to slide by methanol (preferred) or heat description of a Gram stain morphology consistent with (can distort morphology). Corynebacterium and related genera. • Crystal violet is added to the slide. Diphtheroid: clinical microbiology-speak for coryneform • Iodine is added and forms a complex with crystal violet gram-positive rods (Corynebacterium and related genera). that binds to the thick peptidoglycan layer of gram-posi- Gram-negative: bacteria that do not retain the purple color tive cell walls. of the crystal violet in the Gram stain due to the presence • Acetone-alcohol solution is added, which washes away of a thin peptidoglycan cell wall; gram-negative bacteria the crystal violet–iodine complexes in gram-negative appear pink due to the safranin counter stain.
    [Show full text]
  • Bugs & Drugs Antimicrobial Pocket Reference 2001
    Bugs & Drugs Antimicrobial Pocket Reference 2001 FOREWORD Authors (unless otherwise noted) & Editors: Edith Blondel-Hill, MD, FRCP(C) Associate Medical Officer of Health Infectious Diseases Specialist/Medical Microbiologist Capital Health/DKML and Susan Fryters, B.Sc.Pharm. Antimicrobial Utilization/Infectious Diseases Pharmacist Capital Health in collaboration with: · Regional Antimicrobial Advisory Subcommittee · Antimicrobial Working Group (Dr. E. Blondel-Hill, S. Fryters, Dr. M. Foisy, Dr. E. Friesen, M. Gray, R. Muzyka, Dr. P. Robertson, C. Zenuk) · Therapeutic Drug Monitoring (TDM) Task Force (Dr. G. Blakney, Dr. E. Blondel-Hill, S. Fryters, M. Gray, Dr. D. LeGatt, Dr. N. Yuksel) · Antibiotics in Dentistry Working Group (Dr. E. Blondel-Hill, Dr. T. Carlyle, Dr. K. Compton, Dr. T. Debevc, S. Fryters, Dr. D. Gotaas, Dr. K. Kowalewska-Grochowska, Dr. K. Lung, Dr. T. Mather, Dr. H. McLeod, M. Mehta, Dr. J. Nigrin, Dr. S. Ponich, Dr. B. Preshing, Dr. J. Robinson, Dr. S. Shafran) · Divisions of Adult and Paediatric Infectious Diseases · Dynacare Kasper Medical Laboratories (DKML) · UAH Medical Microbiology Department · Regional Pharmacy Services · Regional Public Health · Antibiotics Working Group of AMA Clinical Practice Guidelines Program Secretarial Support: L. Clarke The authors are indebted to Laura Lee Clarke for her outstanding preparation of this manuscript. Editorial Contributions: Dr. J. Galbraith, Infectious Diseases/Medical Microbiologist Ms. M. Gray, BSP Dr. A. Joffe, Paediatric Infectious Diseases Dr. J. Nigrin, Medical Microbiologist Dr. S. Shafran, Adult Infectious Diseases Ms. C. Zenuk, BSP Cover Design: A. Hill Funding provided by: Capital Health Regional Pharmacy Services & Dynacare Kasper Medical Laboratories While every effort has been made to ensure the accuracy of the information presented, the authors, Capital Health, and DKML cannot accept liability for errors or any consequences arising from its use.
    [Show full text]
  • Localized Whirlpool Folliculitis in a Football Player Justin J
    Localized Whirlpool Folliculitis in a Football Player Justin J. Green, MD, Camden, New Jersey Pseudomonas aeruginosa folliculitis occurs in pa- lege football player, sustained a left ankle inversion tients exposed to contaminated water. Most out- sprain 2 days previously. Examination revealed mul- breaks are associated with whirlpools. The infec- tiple, 2- to 6-mm erythematous papules and pustules. tion is characterized by follicular, erythematous The pustules had a distinct light green hue with a cir- papules and pustules located on immersed body cumferential border of intense erythema (Figure 1). surfaces. Most reported cases are the result of Many of the papules and pustules were folliculo- recreational water use, occur in a diffuse pattern, centric. The eruption was clustered in two areas, and are devoid of green pustular pigment changes. separated by a few centimeters, on the medial aspect The case described occurred in a football player of the left leg. The area was tender, but without after whirlpool treatment for an ankle strain. Green edema, and the base of surrounding skin was non- pustules and a localized affected area are unusual erythematous. There was no associated lym- aspects of this case. phadenopathy. Further questioning revealed that the patient received a 20-minute hot whirlpool seudomonas aeruginosa is an aerobic, motile, treatment exclusively to the left leg (distal to the gram-negative rod that inhabits areas of mois- knee), approximately 24 hours prior to the eruption. P ture. The organism can live in sinks, jet fuel, Treatment with 250 mg ciprofloxacin orally twice antiseptic solutions, soil, sewage, flowers, vegetables, daily for 7 days was initiated, but follow-up revealed insects, and warm- and cold-blooded animals.1,2 It can that the patient took just one dose.
    [Show full text]